Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

They essentially offer all the benefits of traditional flossing, but unlike dental floss or dental picks, they are time-efficient, easy to use, and comfortable to hold. Most of the best water ...

After hours: February 7 at 6:59:33 PM EST Loading Chart for SFIX ...

Making the world smarter, happier, and richer.

Days before President Donald Trump took office a second time, the Department of Health and Human Services granted Moderna $590 million for the development of mRNA vaccines for bird flu and other ...